Uterine fibroids are common in females of reproductive age and substantially affecting fertility and quality of life. Current management strategies mainly involve surgical interventions. For treatment, options available are surgical and non-surgical, but the mode of management leans on several factors, such as severity of symptoms, patient’s age, myoma characteristics, desire to preserve uterus and fertility. Alternative approach to surgery for the treatment of symptomatic females with uterine myomas has been recognized. Ulipristal acetate (UPA) has been the first selective progesterone-receptor modulator (SPRM) approved for the pre-operative and long-term management of uterine fibroids. There are evidences promoting an important role for progesterone pathways in the pathophysiology of uterine fibroids which supports the use of ulipristal acetate. The availability of alternative choices to surgical intervention is very necessary especially for those willing to preserve uterus and fertility. One of the alternatives is with ulipristal acetate, which has been proven to treat fibroid symptoms effectively.
References
[1]
Baird, D.D., et al. (2003) High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. The American Journal of Obstetrics and Gynecology, 188, 100-107. https://doi.org/10.1067/mob.2003.99
[2]
Kim, J.J. and Sefton, E.C. (2012) The Role of Progesterone Signaling in the Pathogenesis of Uterine Leiomyoma. Molecular and Cellular Endocrinology, 358, 223-231. https://doi.org/10.1016/j.mce.2011.05.044
[3]
Wilson, R.D. and Langlois, S. (2016) Facteurs genetiques a prendre en consideration dans le cadre de l’examen gynecologique annuel. Journal of Obstetrics and Gynaecology Canada, 38, S22-S33. https://doi.org/10.1016/j.jogc.2016.09.017
[4]
Donnez, J. and Jadoul, P. (2002) What Are the Implications of Myomas on Fertility? A Need for a Debate? Human Reproduction, 17, 1424-1430. https://doi.org/10.1093/humrep/17.6.1424
[5]
Donnez, J., Donnez, O. and Dolmans, M.M. (2014) With the Advent of Selective Progesterone Receptor Modulators, What Is the Place of Myoma Surgery in Current Practice? Fertility and Sterility, 102, 640-648. https://doi.org/10.1016/j.fertnstert.2014.06.041
[6]
Fuldeore, M.J. and Soliman, A.M. (2017) Patient-Reported Prevalence and Symptomatic Burden of Uterine Fibroids among Women in the United States: Findings from a Cross-Sectional Survey Analysis. International Journal of Women’s Health, 9, 403-411. https://doi.org/10.2147/IJWH.S133212
[7]
Donnez, J. and Dolmans, M.M. (2016) Uterine Fibroid Management: From the Present to the Future. Human Reproduction Update, 22, 665-686. https://doi.org/10.1093/humupd/dmw023
[8]
Vilos, G.A., et al. (2015) The Management of Uterine Leiomyomas. Journal of Obstetrics and Gynaecology Canada, 37, 157-178. https://doi.org/10.1016/S1701-2163(15)30338-8
[9]
Donnez, J., et al. (2015) Current Management of Myomas: The Place of Medical Therapy with the Advent of Selective Progesterone Receptor Modulators. Current Opinion in Obstetrics and Gynecology, 27, 422-431. https://doi.org/10.1097/GCO.0000000000000229
[10]
Safrai, M., et al. (2017) Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas. Obstetrics & Gynecology, 130, 315-318. https://doi.org/10.1097/AOG.0000000000002143
[11]
Laberge, P.Y., et al. (2019) Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas—An Addendum. Journal of Obstetrics and Gynaecology Canada, 41, 1521-1524. https://doi.org/10.1016/j.jogc.2019.01.010
[12]
Cramer, S.F., et al. (2000) Relationship of Myoma Cell Size and Menopausal Status in Small Uterine Leiomyomas. Archives of Pathology & Laboratory Medicine, 124, 1448-1453. https://doi.org/10.5858/2000-124-1448-ROMCSA
[13]
Singh, S.S. and Belland, L. (2015) Contemporary Management of Uterine Fibroids: Focus on Emerging Medical Treatments. Current Medical Research and Opinion, 31, 1-12. https://doi.org/10.1185/03007995.2014.982246
[14]
Pritts, E.A., Parker, W.H. and Olive, D.L. (2009) Fibroids and Infertility: An Updated Systematic Review of the Evidence. Fertility and Sterility, 91, 1215-1223. https://doi.org/10.1016/j.fertnstert.2008.01.051
[15]
Khan, A.T., Shehmar, M. and Gupta, J.K. (2014) Uterine Fibroids: Current Perspectives. International Journal of Women’s Health, 6, 95-114. https://doi.org/10.2147/IJWH.S51083
[16]
Doherty, L., et al. (2014) Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive Sciences, 21, 1067-1092. https://doi.org/10.1177/1933719114533728
[17]
Talaulikar, V.S. and Manyonda, I. (2012) Progesterone and Progesterone Receptor Modulators in the Management of Symptomatic Uterine Fibroids. European Journal of Obstetrics & Gynecology and Reproductive Biology, 165, 135-140. https://doi.org/10.1016/j.ejogrb.2012.07.023
[18]
Nisolle, M., et al. (1999) Immunohistochemical Study of the Proliferation Index, Oestrogen Receptors and Progesterone Receptors A and B in Leiomyomata and Normal Myometrium during the Menstrual Cycle and under Gonadotrophin-Releasing Hormone Agonist Therapy. Human Reproduction, 14, 2844-2850. https://doi.org/10.1093/humrep/14.11.2844
[19]
Tamaya, T., Fujimoto, J. and Okada, H. (1985) Comparison of Cellular Levels of Steroid Receptors in Uterine Leiomyoma and Myometrium. Acta Obstetricia et Gynecologica Scandinavica, 64, 307-309. https://doi.org/10.3109/00016348509155136
[20]
Biglia, N., et al. (2014) Ulipristal Acetate: A Novel Pharmacological Approach for the Treatment of Uterine Fibroids. Drug Design, Development and Therapy, 8, 285-292. https://doi.org/10.2147/DDDT.S54565
[21]
Bouchard, P., Chabbert-Buffet, N. and Fauser, B.C. (2011) Selective Progesterone Receptor Modulators in Reproductive Medicine: Pharmacology, Clinical Efficacy and Safety. Fertility and Sterility, 96, 1175-1189. https://doi.org/10.1016/j.fertnstert.2011.08.021
[22]
Chabbert-Buffet, N., Esber, N. and Bouchard, P. (2014) Fibroid Growth and Medical Options for Treatment. Fertility and Sterility, 102, 630-639. https://doi.org/10.1016/j.fertnstert.2014.07.1238
[23]
Tsigkou, A., et al. (2015) Increased Progesterone Receptor Expression in Uterine Leiomyoma: Correlation with Age, Number of Leiomyomas, and Clinical Symptoms. Fertility and Sterility, 104, 170-5.e1. https://doi.org/10.1016/j.fertnstert.2015.04.024
[24]
Donnez, J., et al. (2016) Long-Term Medical Management of Uterine Fibroids with Ulipristal Acetate. Fertility and Sterility, 105, 165-173.e4. https://doi.org/10.1016/j.fertnstert.2015.09.032
[25]
Ishikawa, H., et al. (2010) Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma. Endocrinology, 151, 2433-2442. https://doi.org/10.1210/en.2009-1225
[26]
Arendas, K. and Leyland, N.A. (2016) Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding. Journal of Obstetrics and Gynaecology Canada, 38, 80-83. https://doi.org/10.1016/j.jogc.2015.11.005
[27]
Donnez, J., et al. (2012) Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. The New England Journal of Medicine, 366, 421-432. https://doi.org/10.1056/NEJMoa1103180
[28]
Donnez, J., et al. (2012) Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery. The New England Journal of Medicine, 366, 409-420. https://doi.org/10.1056/NEJMoa1103182
[29]
Xu, Q., et al. (2006) Progesterone Receptor Modulator CDB-2914 Down-Regulates Vascular Endothelial Growth Factor, Adrenomedullin and Their Receptors and Modulates Progesterone Receptor Content in Cultured Human Uterine Leiomyoma Cells. Human Reproduction, 21, 2408-2416. https://doi.org/10.1093/humrep/del159
[30]
Van den Bosch, T., et al. (2015) Terms, Definitions and Measurements to Describe Sonographic Features of Myometrium and Uterine Masses: A Consensus Opinion from the Morphological Uterus Sonographic Assessment (MUSA) Group. Ultrasound in Obstetrics & Gynecology, 46, 284-298. https://doi.org/10.1002/uog.14806
[31]
Chiappini, S. and Schifano, F. (2018) Is There a Potential of Misuse for Quetiapine? Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions’ Database. Journal of Clinical Psychopharmacology, 38, 72-79. https://doi.org/10.1097/JCP.0000000000000814
[32]
Baggio, S., et al. (2018) Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound. Journal of Ultrasound in Medicine, 37, 2215-2223. https://doi.org/10.1002/jum.14573
[33]
Donnez, J., et al. (2014) Long-Term Treatment of Uterine Fibroids with Ulipristal Acetate. Fertility and Sterility, 101, 1565-1573.e1-18. https://doi.org/10.1016/j.fertnstert.2014.02.008
[34]
Luyckx, M., et al. (2014) First Series of 18 Pregnancies after Ulipristal Acetate Treatment for Uterine Fibroids. Fertility and Sterility, 102, 1404-1409. https://doi.org/10.1016/j.fertnstert.2014.07.1253
[35]
Murad, K. (2016) Spontaneous Pregnancy Following Ulipristal Acetate Treatment in a Woman with a Symptomatic Uterine Fibroid. Journal of Obstetrics and Gynaecology Canada, 38, 75-79. https://doi.org/10.1016/j.jogc.2015.11.004
[36]
Donnez, J., Donnez, O. and Dolmans, M.M. (2016) Safety of Treatment of Uterine Fibroids with the Selective Progesterone Receptor Modulator, Ulipristal Acetate. Expert Opinion on Drug Safety, 15, 1679-1686. https://doi.org/10.1080/14740338.2016.1248943
[37]
Murji, A., et al. (2017) Selective Progesterone Receptor Modulators (SPRMs) for Uterine Fibroids. The Cochrane Database of Systematic Reviews, 4, Cd010770. https://doi.org/10.1002/14651858.CD010770.pub2
[38]
Esteve, J.L., et al. (2012) Treatment of Uterine Myoma with 5 or 10 mg Mifepristone Daily during 6 Months, Post-Treatment Evolution over 12 Months: Double-Blind Randomised Clinical Trial. European Journal of Obstetrics & Gynecology and Reproductive Biology, 161, 202-208. https://doi.org/10.1016/j.ejogrb.2011.12.018
[39]
Kale, A.R. (2018) Comparison between Mifepristone and Ulipristal Acetate as an Alternative to Surgical Management of Uterine Fibroids (Leiomyoma) in Symptomatic Patients of Reproductive Age Group in Asian Population. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 7, 109-113. https://doi.org/10.18203/2320-1770.ijrcog20175528
[40]
Brache, V., et al. (2013) Ulipristal Acetate Prevents Ovulation More Effectively than Levonorgestrel: Analysis of Pooled Data from Three Randomized Trials of Emergency Contraception Regimens. Contraception, 88, 611-618. https://doi.org/10.1016/j.contraception.2013.05.010
[41]
Glasier, A.F., et al. (2010) Ulipristal Acetate versus Levonorgestrel for Emergency Contraception: A Randomised Non-Inferiority Trial and Meta-Analysis. The Lancet, 375, 555-562. https://doi.org/10.1016/S0140-6736(10)60101-8
[42]
Creinin, M.D., et al. (2006) Progesterone Receptor Modulator for Emergency Contraception: A Randomized Controlled Trial. Obstetrics & Gynecology, 108, 1089-1097. https://doi.org/10.1097/01.AOG.0000239440.02284.45
[43]
Fine, P., et al. (2010) Ulipristal Acetate Taken 48-120 Hours after Intercourse for Emergency Contraception. Obstetrics & Gynecology, 115, 257-263. https://doi.org/10.1097/AOG.0b013e3181c8e2aa
[44]
Rendic, S. and Guengerich, F.P. (2010) Update Information on Drug Metabolism Systems—2009, Part II: Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters. Current Drug Metabolism, 11, 4-84. https://doi.org/10.2174/138920010791110917
[45]
Thummel, K.E. and Wilkinson, G.R. (1998) In Vitro and in Vivo Drug Interactions Involving Human CYP3A. Annual Review of Pharmacology and Toxicology, 38, 389-430. https://doi.org/10.1146/annurev.pharmtox.38.1.389
[46]
Melis, G.B., et al. (2012) Pharmacokinetic Evaluation of Ulipristal Acetate for Uterine Leiomyoma Treatment. Expert Opinion on Drug Metabolism & Toxicology, 8, 901-908. https://doi.org/10.1517/17425255.2012.695775
